Equities research analysts expect PDL BioPharma, Inc. (NASDAQ:PDLI) to post earnings of $0.08 per share for the current quarter, according to Zacks. Zero analysts have made estimates for PDL BioPharma’s earnings, with estimates ranging from $0.05 to $0.10. PDL BioPharma posted earnings of $0.11 per share in the same quarter last year, which would indicate a negative year over year growth rate of 27.3%. The business is expected to report its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that PDL BioPharma will report full year earnings of $0.38 per share for the current fiscal year, with EPS estimates ranging from $0.15 to $0.60. For the next year, analysts expect that the firm will report earnings of $0.31 per share, with EPS estimates ranging from $0.05 to $0.56. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover PDL BioPharma.

PDL BioPharma (NASDAQ:PDLI) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.17. PDL BioPharma had a net margin of 23.03% and a return on equity of 9.07%. The firm had revenue of $143.80 million during the quarter, compared to the consensus estimate of $56.30 million. During the same period in the prior year, the firm earned $0.09 EPS. The business’s revenue was up 584.8% on a year-over-year basis.

PDLI has been the topic of several research reports. ValuEngine upgraded shares of PDL BioPharma from a “hold” rating to a “buy” rating in a report on Friday, August 4th. BidaskClub downgraded shares of PDL BioPharma from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Zacks Investment Research upgraded shares of PDL BioPharma from a “sell” rating to a “hold” rating in a report on Monday, May 15th. Cowen and Company reiterated a “hold” rating on shares of PDL BioPharma in a report on Wednesday, May 3rd. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $4.00 price objective on shares of PDL BioPharma in a report on Thursday, August 10th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. PDL BioPharma presently has a consensus rating of “Buy” and a consensus price target of $3.50.

Shares of PDL BioPharma (NASDAQ PDLI) traded down 2.15% during mid-day trading on Thursday, reaching $2.73. 1,664,209 shares of the company’s stock were exchanged. PDL BioPharma has a 52-week low of $1.93 and a 52-week high of $3.77. The stock’s 50-day moving average is $2.47 and its 200-day moving average is $2.30. The stock has a market cap of $420.64 million, a price-to-earnings ratio of 6.28 and a beta of 0.58.

COPYRIGHT VIOLATION WARNING: This story was published by American Banking News and is the property of of American Banking News. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/08/17/0-08-eps-expected-for-pdl-biopharma-inc-pdli-this-quarter.html.

Institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP increased its position in PDL BioPharma by 15.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,282,180 shares of the biotechnology company’s stock valued at $9,078,000 after buying an additional 582,265 shares in the last quarter. HPM Partners LLC bought a new position in PDL BioPharma during the first quarter valued at approximately $163,000. Seizert Capital Partners LLC bought a new position in PDL BioPharma during the first quarter valued at approximately $2,706,000. Norges Bank bought a new position in PDL BioPharma during the fourth quarter valued at approximately $5,068,000. Finally, Brandes Investment Partners LP bought a new position in PDL BioPharma during the first quarter valued at approximately $133,000. Hedge funds and other institutional investors own 87.72% of the company’s stock.

About PDL BioPharma

PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.

Get a free copy of the Zacks research report on PDL BioPharma (PDLI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for PDL BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.